Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SPM002
- Development stage
- Preclinical
- Lead developer
- SPIMA Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Peptides
01
Overview
SPM002 is a preclinical-stage peptide-based proteolysis-targeting chimera (P-PROTAC) being developed by SPIMA Therapeutics. Utilizing the company's proprietary P-PROTAC platform, the molecule is designed to selectively degrade intracellular proteins that are traditionally considered "undruggable," such as transcription factors or scaffolding proteins. By employing a peptide ligand rather than a small molecule to bind the target protein, P-PROTACs aim to achieve high specificity and improved solubility. SPM002 is currently positioned for the treatment of various cancers, although its specific molecular target remains undisclosed by the developer as of 2024.
- Other names
- SPM002SPM-002SPM 002
Beyond the preview
Go deeper on SPM002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SPM002.